FGFR2 and cholangiocarcinoma: Notably, futibatinib has demonstrated some activity in patients previously treated with anti-FGFR agents, and both derazatinib and futibatinib have demonstrated similar activity in CCA with FGFR2 mutations as those with FGFR2 fusions/rearrangements [40,41].